Earnings summaries and quarterly performance for Upstream Bio.
Executive leadership at Upstream Bio.
Board of directors at Upstream Bio.
Research analysts covering Upstream Bio.
Recent press releases and 8-K filings for UPB.
Upstream Bio Reports Positive Phase 2 VALIANT Trial Results and Financial Position
UPB
New Projects/Investments
Guidance Update
- Upstream Bio, Inc. announced positive top-line results from its Phase 2 VALIANT clinical trial of verekitug in severe asthma, which met the primary endpoint of reduction in Annualized Asthma Exacerbation Rates (AAER).
- The 100mg q12w dose of verekitug demonstrated a 56% reduction in AAER (p<0.0003), and the 400mg q24w dose showed a 39% reduction in AAER (p<0.02), both with clinically meaningful improvements in lung function and exhaled nitric oxide.
- The company reported preliminary unaudited estimates of cash, cash equivalents, and short-term investments of approximately $341.5 million as of December 31, 2025.
- This financial position is expected to fund planned operations through 2027 , with plans to begin Phase 3 trials in severe asthma and CRSwNP in 2027 after integrated analyses of Phase 2 data in 2026.
Feb 11, 2026, 2:17 PM
Upstream Bio Announces Positive Top-line Results for Phase 2 VALIANT Trial in Severe Asthma
UPB
- Upstream Bio announced positive top-line results for its Phase 2 VALIANT trial in severe asthma on February 11, 2026.
- The study met its primary endpoint, demonstrating statistically significant and clinically meaningful reductions in annualized asthma exacerbation rates (AAER) with verekitug.
- The 100mg every 12 weeks dose showed a 56% reduction in AAER (p<0.0003) and a 122mL improvement in FEV1, while the 400mg every 24 weeks dose resulted in a 39% reduction in AAER (p<0.02) and a 139mL improvement in FEV1.
- Verekitug was generally well tolerated, with a safety profile consistent with prior studies.
- The company reported cash, cash equivalents, and short-term investments of approximately $341.5 million as of December 31, 2025, which are expected to fund planned operations through 2027.
Feb 11, 2026, 1:00 PM
Upstream Bio Announces Positive Phase II VALIANT Trial Results for Verekitug in Severe Asthma
UPB
New Projects/Investments
- Upstream Bio announced positive top-line data from its VALIANT phase II trial of verekitug in adults with severe asthma, demonstrating statistically significant and clinically meaningful reductions in the annualized rate of asthma exacerbations (AAER).
- Verekitug administered at 100 milligrams every 12 weeks resulted in a 56% reduction in AAER, and 400 milligrams every 24 weeks resulted in a 39% reduction in AAER compared to placebo.
- Both regimens also showed clinically meaningful improvements in lung function (FEV1) and exhaled nitric oxide (FeNO), with a favorable safety profile consistent with previous studies.
- The company plans to advance verekitug into phase III studies for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), aiming for significantly less frequent dosing than currently available biologics.
Feb 11, 2026, 1:00 PM
Upstream Bio Reports Positive Phase 2 VALIANT Trial Results for Verekitug in Severe Asthma
UPB
New Projects/Investments
- Upstream Bio announced positive top-line results from its Phase 2 VALIANT trial of Verekitug in adults with severe asthma.
- The trial demonstrated a statistically significant and clinically meaningful reduction in the annualized rate of asthma exacerbations (AAER). Specifically, Verekitug achieved a 56% reduction in AAER with 100 mg administered every 12 weeks and a 39% reduction with 400 mg administered every 24 weeks.
- Both treatment regimens also showed clinically meaningful improvements in lung function (FEV1) and exhaled nitric oxide (FeNO), and Verekitug was generally well-tolerated with a favorable safety profile.
- Upstream Bio plans to advance Verekitug into Phase 3 studies in both severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), pending interactions with regulatory authorities.
- The company is also progressing enrollment in its Phase 2 VENTURE trial for COPD, which is over 60% complete.
Feb 11, 2026, 1:00 PM
Upstream Bio Announces Positive Phase 2 VALIANT Trial Results for Verekitug in Severe Asthma
UPB
- Upstream Bio reported positive top-line data from its Phase 2 VALIANT trial for verekitug in adults with severe asthma, demonstrating a statistically significant and clinically meaningful reduction in the annualized rate of asthma exacerbations (AAER).
- The 100 milligrams every 12 weeks regimen achieved a 56% reduction in AAER, a 122 milliliter improvement in FEV1, and a 43.5% reduction in exhaled nitric oxide (FeNO) from baseline.
- The 400 milligrams every 24 weeks regimen showed a 39% reduction in AAER, a 139 milliliter improvement in FEV1, and a 44.9% reduction in FeNO versus baseline.
- Verekitug was generally well-tolerated across all dose regimens, and the company plans to advance it into Phase 3 studies for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP).
Feb 11, 2026, 1:00 PM
Upstream Bio Reports Positive Phase 2 VALIANT Trial Results for Verekitug in Severe Asthma
UPB
New Projects/Investments
- On February 11, 2026, Upstream Bio, Inc. announced positive top-line results from its Phase 2 VALIANT clinical trial evaluating verekitug for the treatment of severe asthma.
- The trial met its primary endpoint, demonstrating a statistically significant reduction in the annualized asthma exacerbation rate (AAER) of 56% with 100 mg q12w dosing and 39% with 400 mg q24w dosing, compared to placebo.
- Verekitug also showed clinically meaningful improvements in lung function (FEV1) and exhaled nitric oxide (FeNO) with both the 100 mg q12w and 400 mg q24w dose regimens, and was generally well tolerated with a favorable safety profile.
- Upstream Bio plans to advance verekitug into Phase 3 trials for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) following planned regulatory interactions.
Feb 11, 2026, 11:38 AM
Upstream Bio Provides Update on Verekitug Clinical Development and Market Opportunity
UPB
Product Launch
New Projects/Investments
- Upstream Bio's CEO, Rand Sutherland, presented on verekitug, a TSLP receptor-targeting drug, highlighting its differentiated profile with 100% receptor occupancy for up to 24 weeks and potential for every 12-week or 24-week dosing.
- The company reported positive Phase 2 results for verekitug in chronic rhinosinusitis with nasal polyps (CRS with NP), showing a 1.8-point reduction in endoscopic nasal polyp score and a 76% reduction in the need for surgery or steroids.
- The severe asthma study (Valiant) data readout is anticipated this quarter (Q1 2026), with the trial powered to detect a 50% reduction in asthma exacerbations.
- Upstream Bio is targeting multi-billion dollar markets in severe asthma, CRS with NP, and COPD, aiming for differentiated efficacy and broad patient populations.
Jan 12, 2026, 10:15 PM
Upstream Bio Highlights Positive Phase 2 Data for Virecetug in CRS with NP and Upcoming Severe Asthma Readout
UPB
New Projects/Investments
- Upstream Bio, a clinical-stage company, is developing Virecetug, a drug targeting the TSLP receptor for severe respiratory diseases, including chronic rhinosinusitis with nasal polyps (CRS with NP), severe asthma, and chronic obstructive pulmonary disease (COPD).
- Recent Phase 2 trial data for CRS with NP showed a statistically and clinically significant reduction of 1.8 points in endoscopic nasal polyp score and a 76% reduction in the need for surgery or steroids.
- The company expects to read out Phase 2 data for severe asthma by the end of Q1 2026. This trial is powered to detect a 50% or greater reduction in annualized asthma exacerbation rates.
- Virecetug demonstrates unique pharmacology, including 100% receptor occupancy for up to 24 weeks after the last dose, enabling infrequent dosing (two or four times per year), and has maintained a clean safety profile across studies.
Jan 12, 2026, 10:15 PM
Upstream Bio Reports Positive Phase 2 CRSwNP Results and Provides Pipeline Update
UPB
Product Launch
New Projects/Investments
Guidance Update
- Upstream Bio, a clinical-stage immunology company, is developing vereitug, the only known clinical-stage antagonist of the TSLP receptor, for severe respiratory diseases.
- The VIBRANT Phase 2 trial for chronic rhinosinusitis with nasal polyps (CRSwNP) reported positive top-line results in September 2025, demonstrating a -1.8 reduction in nasal polyp score (NPS) (p<0.0001) and a 76% reduction in the need for surgery/steroids with 12-week dosing.
- Upcoming catalysts include top-line results for the VALIANT Phase 2 trial in severe asthma, expected in Q1 2026, while the VENTURE Phase 2 trial in COPD is actively enrolling.
- Verekitug has shown high potency in asthma patients, with a modeled effect on FENO that is ~1.5 times greater than tezepelumab and >300-fold lower EC50/EC90, enabling potential extended dosing intervals of up to 24 weeks.
- The company's existing capital is expected to fund planned operations through 2027, addressing a global biologics market for asthma and COPD projected to exceed $35 billion by mid-2030s.
Jan 12, 2026, 10:15 PM
Upstream Bio Highlights Positive Phase 2 Data for Virecetug in CRS with NP and Upcoming Asthma Data
UPB
New Projects/Investments
- Upstream Bio, a clinical-stage company, is developing Virecetug, a drug targeting the TSLP receptor for severe respiratory diseases, with potential for infrequent dosing (two or four times per year).
- Recent Phase 2 data for chronic rhinosinusitis with nasal polyps (CRS with NP) demonstrated a significant and statistically significant reduction in endoscopic nasal polyp score of 1.8 points and a 76% reduction in the need for surgery or steroids, alongside an unblemished safety profile.
- The Phase 2 severe asthma trial (Valiant) is expected to report data in Q1 2026, and is powered to detect a 50% or greater reduction in annualized asthma exacerbation rates.
- A Phase 2 trial in chronic obstructive pulmonary disease (COPD) has also recently commenced enrollment.
- The company aims for Virecetug to offer a differentiated profile with best-in-class efficacy and less frequent dosing across a broad patient population in multi-billion dollar markets.
Jan 12, 2026, 10:15 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more